₨488.00
Yes
Mirtazapine
Depression
Mirtazapine is a centrally active presynaptic a2 -antagonist, which increases central noradrenergic and serotonergic neurotransmission. The enhancement of serotonergic neurotransmission is specifically mediated via 5-HT1 receptors, because 5-HT2 and 5-HT3 receptors are blocked by Mirtazapine. The histamine H1-antagonistic activity of Mirtazapine is associated with its sedative properties.
Adults : Initial starting dose is 15mg once daily at night. Titrate according to response , usually 15-45mg as a single dose at night or in two equally divided doses morning and night. Withdraw gradually when symptoms free 4-6 months. Children : Not recommended. OR As directed by your physician .
Bone marrow depression (granulocytope-nia, agranulo-cytosis, aplastic anaemia, thrombo-cytopenia) , Eosinophilia , Weight increased , Increase in appetite Abnormal dreams , Confusion , Anxiety , Insomnia , Nightmares , Mania , Agitation , Hallucinations , Psychomotor restlessness (incl. akathisia, hyperkinesia) , Aggression , Suicidal ideation , Suicidal behaviour , Somnolence Sedation , Headache , Lethargy , Dizziness , Tremor , Paraesthesia , Restless legs, Syncope, Myoclonus , Convulsions (insults) , Serotonin syndrome , Oral paresthaesia , Dysarthria.
MAO inhibitors , SSRIs , benzodiazepines and other sedatives (notably most antipsychotics, histamine H1 antagonists, opioids , alcohol.
Treatment of episodes of major depression in adults.
• Hypersensitivity to the active substance • Concomitant use of Mirtazapine with monoamine oxidase (MAO) inhibitors.
Mirtazapine should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviors (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behavior and anger) may occur among children and adolescents treated with antidepressants.
The patient should be carefully monitored for the appearance of suicidal symptoms.
Bone marrow depression, usually presenting as granulocytopenia or agranulocytosis, may occur rarely during treatment with Mirtazapine.
Treatment should be discontinued if jaundice occurs.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.